1. P2-Quinazolinones and Bis-Macrocycles as New Templates for Next-Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK-2748 and MK-6325
- Author
-
Anne Taylor, Charles J. Mcintyre, Christine Fandozzi, Carolyn McHale, Jillian DiMuzio, Steven Harper, Steven S. Carroll, Vincenzo Summa, Jeff Fritzen, Aileen Soriano, Marco Ferrara, Joseph J. Romano, David B. Olsen, Kevin Nguyen, Steven W. Ludmerer, Nigel J. Liverton, Robert Chase, Stuart Black, John W. Butcher, Kevin F. Gilbert, Qian Huang, Michael T. Rudd, Adam Gates, Paul J. Coleman, Marcello DiFilippo, Mark Stahlhut, Kimberly J. Bush, John Swestock, Nicole Trainor, Christine Burlein, Stephanie McClain, John A. McCauley, M. Katharine Holloway, Donald J. Graham, Rudd, Mt, Butcher, Jw, Nguyen, Kt, Mcintyre, Cj, Romano, Jj, Gilbert, Kf, Bush, Kj, Liverton, Nj, Holloway, Mk, Harper, S, Ferrara, M, Difilippo, M, Summa, V, Swestock, J, Fritzen, J, Carroll, S, Burlein, C, Dimuzio, Jm, Gates, A, Graham, Qian Huang, Dj, Mcclain, S, Mchale, C, Stahlhut, Mw, Black, S, Chase, R, Soriano, A, Fandozzi, C, Taylor, A, Trainor, N, Olsen, Db, Coleman, Pj, Ludmerer, Sw, and Mccauley, Ja
- Subjects
Models, Molecular ,Macrocyclic Compounds ,medicine.medical_treatment ,Mutant ,Hepacivirus ,Viral Nonstructural Proteins ,Biology ,Crystallography, X-Ray ,Antiviral Agents ,Biochemistry ,Virus ,Drug Discovery ,Genotype ,medicine ,Hepatitis C Virus NS3/4A Protease Inhibitors ,Animals ,Humans ,Potency ,Sulfones ,General Pharmacology, Toxicology and Pharmaceutics ,Quinazolinones ,Pharmacology ,NS3 ,Protease ,Organic Chemistry ,Hepatitis C ,medicine.disease ,Rats ,Mutation ,Molecular Medicine - Abstract
With the goal of identifying inhibitors of hepatitis C virus (HCV) NS3/4a protease that are potent against a wide range of genotypes and clinically relevant mutant viruses, several subseries of macrocycles were investigated based on observations made during the discovery of MK-5172. Quinazolinone-containing macrocycles were identified as promising leads, and optimization for superior cross-genotype and mutant enzyme potency as well as rat liver and plasma concentrations following oral dosing, led to the development of MK-2748. Additional investigation of a series of bis-macrocycles containing a fused 18- and 15-membered ring system were also optimized for the same properties, leading to the discovery of MK-6325. Both compounds display the broad genotype and mutant potency necessary for clinical development as next-generation HCV NS3/4a protease inhibitors.
- Published
- 2015
- Full Text
- View/download PDF